bullish
Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal
546 Views11 Dec 2019 09:20
Alphamab, the leading bispecific antibodies player in China, raised USD 220 million at HKD 10.2 per share. In this insight, we will cover the...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Powerlong Commercial IPO Trading - Good Subscription Results but Issues Remain29 Dec 2019
- ECM Weekly (23 Dec 2019) - Bank of Guizhou, Powerlong Commercial Management23 Dec 2019
- ECM Weekly (14 Dec 2019) - SBI Cards, Poly Property, JS Global, OneConnet14 Dec 2019
- Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal11 Dec 2019
- Alphamab (康宁杰瑞) IPO: You Will Likely Be Zeroed29 Nov 2019
- Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates18 Nov 2019
x